IgA nephropathy, susceptibility to
MONDO:0100555An inherited susceptibility or predisposition to developing IgA glomerulonephritis.
16 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsSub-types
Broader categories
-
Can a new pill slow kidney damage in IgA nephropathy?
Disease control Not yet recruitingThis study is testing whether an experimental drug called FXS6837 can safely reduce protein in the urine and help preserve kidney function in people with IgA nephropathy, a disease that can lead to kidney failure. About 60 patients who previously completed a shorter study of FXS6…
Phase 2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug aims to reduce kidney damage in IgAN patients
Disease control Not yet recruitingThis study tests an experimental drug called FXS6837 in 60 adults with IgA nephropathy, a kidney disease. Participants will receive either the drug or a placebo for about 6 months. The main goal is to see if the drug lowers protein in the urine, a sign of kidney damage.
Phase 2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug aims to slow kidney damage in IgA nephropathy
Disease control Not yet recruitingThis Phase 2 trial tests an experimental drug called HS-10542 in 90 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants will receive either a high dose, low dose, or placebo for a set period. The main goal is to see if the drug reduces prot…
Phase 2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC